- Home
- SGP vs GHRS Comparison
SGP vs GHRS Comparison
Compare SGP & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | GHRS |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | Ireland |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.9M | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGP | GHRS |
|---|---|---|
| Price | $19.22 | $24.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $45.00 | $41.38 |
| AVG Volume (30 Days) | 50.1K | ★ 190.3K |
| Earning Date | 05-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.46 | $10.96 |
| 52 Week High | $30.56 | $24.66 |
Technical Indicators
Market Signals| Indicator | SGP | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 66.60 |
| Support Level | N/A | $12.65 |
| Resistance Level | $26.29 | $24.66 |
| Average True Range (ATR) | 1.59 | 1.55 |
| MACD | -0.38 | -0.04 |
| Stochastic Oscillator | 2.61 | 92.71 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.